Loading clinical trials...
Loading clinical trials...
Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens Through Improved Epidemiologic Methods
Conditions
Interventions
Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)
+1 more
Locations
3
Kazakhstan
Partners In Health, Kazakhstan
Almaty, Kazakhstan
Partners In Health, Lesotho
Maseru, Lesotho
Socios En Salud
Lima, Lima Province, Peru
Start Date
September 22, 2020
Primary Completion Date
December 30, 2025
Completion Date
December 31, 2025
Last Updated
December 5, 2024
NCT01875588
NCT06598397
NCT06857071
NCT06627764
NCT07509853
NCT07512869
Lead Sponsor
Harvard Medical School (HMS and HSDM)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions